Circulating cell‐free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis. (7th January 2019)

• Record Type: Journal Article
• Authors: Polini, Beatrice; Carpi, Sara; Romanini, Antonella; Breschi, Maria Cristina; Nieri, Paola; Podestà, Adriano
• Is Part Of: Pigment cell & melanoma research. Volume 32:Number 4(2019)
• Page Start: 486
• Page End: 499
• Publication Date: 2019-01-07
• Subjects: biomarker -- blood -- circulating cell‐free microRNA -- cutaneous melanoma -- prognosis -- recurrence -- staging; Melanoma -- Periodicals; Chromatophores -- Periodicals; Animal pigments -- Periodicals; 616.99477
• DOI: 10.1111/pcmr.12755
• Languages: English
• ISSNs: 1755-1471

Abstract

Abstract: Cutaneous melanoma is a skin cancer with increasing incidence. Identification of novel clinical biomarkers able to detect the stage of disease and suggest prognosis could improve treatment and outcome for melanoma patients. Cell‐free microRNAs (cf‐miRNAs) are the circulating copies of short non‐coding RNAs involved in gene expression regulation. They are released into the interstitial fluid, are detectable in blood and other body fluids and have interesting features of ideal biomarker candidates. They are stable outside the cell, tissue specific, vary along with cancer development and are sensitive to change in the disease course such as progression or therapeutic response. Moreover, they are accessible by non‐invasive methods or venipuncture. Some articles have reported different cf‐miRNAs with the potential of diagnostic tools for melanoma staging, recurrence and survival prediction. Although some concordance of results is already emerging, differences in analytical methods, normalization strategies and tumour staging still will require further research and standardization prior to clinical usage of cf‐miRNA analysis. This article reviews this literature with the aim of contributing to a shared focusing on these new promising tools for melanoma treatment and care.